Search Results

Your search for William G. Wierda, MD, PhD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / NCCN 2019 Annual Congress: Hematologic Malignancies

William G. Wierda, MD, PhD, on Evolving Strategies for First-Line Treatment of CLL

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, offers commentary on the debate about evolving strategies in first-line chronic lymphocytic leukemia, the clinical trials on such agents as ibrutinib, BTK inhibitors, and venetoclax, and the interest in...

leukemia

lymphoma

immunotherapy

By The ASCO Post Staff / 2019 ASCO Annual Meeting

William G. Wierda, MD, PhD, on Immunotherapy for Relapsed/Refractory CLL/SLL: Results From TRANSCEND CLL 004

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the TRANSCEND CLL 004 trial, which studied the use of an experimental CD19-directed CAR T-cell product in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract ...

Apr

Today In Oncology

Search Results

Your search for William G. Wierda, MD, PhD matches 2 pages

William G. Wierda, MD, PhD, on Evolving Strategies for First-Line Treatment of CLL

William G. Wierda, MD, PhD, on Immunotherapy for Relapsed/Refractory CLL/SLL: Results From TRANSCEND CLL 004

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer

Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved

Potential Protective Effects of Aspirin Against Colorectal Cancer